ABBV News and Press, AbbVie Inc. From 06/27/24

AbbVie Acquires Celsius Therapeutics PR Newswire Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. , June 27, ...

Introducing Allē Payment Plans, Powered by Cherry PR Newswire Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatm...

2024-06-27 05:34:44 ET Genmab ( GMAB ) and partner AbbVie ( NYSE: ABBV ) have received U.S. FDA approval for their monoclonal antibody Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma.... Read the full article ...

2024-06-27 05:30:00 ET Pharma stocks haven't been outstanding investments since the central bank began hiking rates in 2022. The core reason is that these companies depend on innovation to create value for shareholders -- an inherently risky endeavor. AbbVie (NYSE: ABBV) has bee...

U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma PR Newswire - EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or re...

2024-06-26 12:07:34 ET More on Tempur Sealy Tempur Sealy: Bedding Premiumization Offset By Headwinds In U.S. Mattress Market Tempur Sealy International, Inc. (TPX) Q1 2024 Earnings Call Transcript Tempur Sealy drops amid report of meeting with FTC on Mattress Firm; d...

2024-06-25 15:11:25 ET More on Cerevel Therapeutics Cerevel Therapeutics: Time For A Risk Arbitrage Play? Cerevel Therapeutics seesaws amid FTC notice on closed door meeting Cerevel Therapeutics gains after AbbVie says making good progress with FTC Seeking Al...

2024-06-25 09:26:41 ET AbbVie’s ( NYSE: ABBV ) new drug application for its Parkinson’s disease combination therapy has been denied approval by the FDA .... Read the full article on Seeking Alpha For further details see: FDA snubs AbbVie Parkinson's...

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) PR Newswire U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's thir...

2024-06-25 04:31:00 ET If you're looking to pump up your passive income stream, there are a handful of high-yield dividend stocks that deserve your attention. AbbVie (NYSE: ABBV) , Ares Capital (NASDAQ: ARCC) , and Realty Income (NYSE: O) have what it takes to delive...